144 related articles for article (PubMed ID: 38796666)
1. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
Int J Hematol; 2024 May; ():. PubMed ID: 38796666
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis.
Socié G; Niederwieser D; von Bubnoff N; Mohty M; Szer J; Or R; Garrett J; Prahallad A; Wilke C; Zeiser R
Blood; 2023 Jun; 141(22):2771-2779. PubMed ID: 36827620
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.
Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D
Ann Hematol; 2024 Jun; ():. PubMed ID: 38916740
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons.
Tremblay G; Tomaras D; Strati E; Forsythe A
J Health Econ Outcomes Res; 2021 Feb; 8(1):10-17. PubMed ID: 33768123
[No Abstract] [Full Text] [Related]
13. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
Luo C; Huang X; Wei L; Wu G; Huang Y; Ding Y; Huang Z; Chen J; Li X; Zou Y; Xu S
Front Immunol; 2023; 14():1211171. PubMed ID: 37409129
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R; Polverelli N; Ram R; Hashmi SK; Chakraverty R; Middeke JM; Musso M; Giebel S; Uzay A; Langmuir P; Hollaender N; Gowda M; Stefanelli T; Lee SJ; Teshima T; Locatelli F;
N Engl J Med; 2021 Jul; 385(3):228-238. PubMed ID: 34260836
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
18. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
[TBL] [Abstract][Full Text] [Related]
19. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
Front Immunol; 2022; 13():954268. PubMed ID: 35990629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
